GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Stoke Therapeutics
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases using RNA technology. Its stock price is driven by news from its clinical trials. The chart reflects investor hopes for a breakthrough in this complex field.
Share prices of companies in the market segment - Dna
Stoke Therapeutics is a biotech company developing drugs to treat genetic diseases using RNA technology. We classify it as part of the DNA sector, and the chart below reflects the dynamics of this cutting-edge and high-risk field of biotechnology.
Broad Market Index - GURU.Markets
Stoke Therapeutics is a biotech company developing RNA-based drugs to treat severe genetic diseases by enhancing protein expression. It is a component of the GURU.Markets index. The chart below shows the market. See how Stoke shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
STOK - Daily change in the company's share price Stoke Therapeutics
The volatility of Stoke Therapeutics, which works on RNA therapy for rare genetic diseases, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for analysis of the advanced biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Stoke Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of STOK, which focuses on treating rare genetic diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Stoke is a biopharmaceutical company developing RNA-based drugs to treat genetic diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Stoke's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Stoke Therapeutics
Stoke is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Stoke Therapeutics, Inc. is a biotechnology company developing a new class of RNA-based therapies for the treatment of rare genetic diseases. Its innovative platform is its key advantage. Its stock price reflects the high potential of its technology and the risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Stoke Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Stoke Therapeutics
The value of Stoke, a biopharmaceutical company, is speculative. The monthly fluctuations on the chart reflect not revenue, but news about clinical trials of its drugs for rare genetic diseases based on its unique RNA technology.
Monthly dynamics of market capitalization of the market segment - Dna
Stoke Therapeutics, Inc. is a biotechnology company developing a new class of RNA-targeted drugs to increase protein production for the treatment of severe genetic diseases. Its sector performance, shown in the chart, reflects its faith in new technologies, allowing us to assess how its unique scientific approach could transform the treatment of certain rare diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Stoke Therapeutics develops RNA-based drugs to treat severe genetic diseases. This is a cutting-edge but high-risk area of biotechnology. The overall market has little impact on Stoke; its shares are driven by news of clinical trials, and a single successful result could trigger explosive growth, defying any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Stoke Therapeutics
Stoke Therapeutics, a biotech company developing RNA-based drugs to treat rare genetic diseases, is experiencing extreme volatility. Weekly stock performance depends on data from preclinical and clinical trials, where any news can lead to sharp price movements.
Weekly dynamics of market capitalization of the market segment - Dna
Stoke Therapeutics, like other gene therapy companies, is part of the volatile biotech sector. This chart compares its performance with the industry, showing how much of its movements are driven by general biotech sentiment and how much by the unique data from its clinical trials.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Stoke Therapeutics develops drugs to treat rare genetic diseases. Its shares follow their own rhythm, driven by clinical trial results. The chart shows how independent Stoke's performance is from general market fluctuations, driven by its own unique news.
Market capitalization of the company, segment and market as a whole
STOK - Market capitalization of the company Stoke Therapeutics
Stoke Therapeutics' market cap represents a financial bet on an innovative approach to treating genetic diseases. The company's stock price reflects the hopes for its technology, which aims not to replace a gene but to increase protein production from its healthy counterpart. Its performance is a barometer of progress in clinical trials for rare diseases.
STOK - Share of the company's market capitalization Stoke Therapeutics within the market segment - Dna
Stoke Therapeutics is a pioneer in developing RNA-targeted drugs to treat severe genetic diseases by increasing protein expression. Its market cap reflects the potential of its unique TANGO technology platform. The chart below shows how investors view its chances in this cutting-edge field of genetic medicine.
Market capitalization of the market segment - Dna
Stoke Therapeutics is a biotech company working to treat severe genetic diseases using RNA therapy. The chart below shows the total market capitalization of this cutting-edge sector. Its dynamics are a barometer of hopes for a breakthrough in gene medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression. Its market capitalization chart tells the story of a new approach to gene therapy. Its value reflects the hope that this technology will help patients with rare diseases.
Book value capitalization of the company, segment and market as a whole
STOK - Book value capitalization of the company Stoke Therapeutics
For Stoke Therapeutics, which develops RNA-based drugs, book value is its capital and laboratory equipment. The chart below shows the financial foundation for its cutting-edge science. Growth on this chart signifies successful fundraising to advance its unique technology platform.
STOK - Share of the company's book capitalization Stoke Therapeutics within the market segment - Dna
Stoke Therapeutics is a biotech company developing drugs to treat genetic diseases. Its primary asset is its scientific platform. The share of tangible assets will be low, reflecting its focus on R&D, with laboratories serving as the primary focus rather than large manufacturing facilities.
Market segment balance sheet capitalization - Dna
Stoke Therapeutics develops drugs to treat genetic diseases. Its value lies in its unique scientific platform and intellectual property, not in its production assets. The book value chart shows a typical biotech picture: a low tangible asset base with high potential value.
Book value of all companies included in the broad market index - GURU.Markets
Stoke Therapeutics' assets are focused on rare genetic diseases. The company's book value reflects its investments in the TANGO scientific platform and its extensive clinical trials. This provides the material and financial foundation for the development of a new class of RNA-based therapies capable of treating the underlying cause of the disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Stoke Therapeutics
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. The company's book value is small. Its market capitalization represents investors' pure bet on the success of its innovative scientific platform, TANGO. The chart reflects the level of optimism regarding future clinical data.
Market to book capitalization ratio in a market segment - Dna
Stoke Therapeutics develops drugs to treat severe genetic diseases. Its value lies in its unique scientific platform. The chart demonstrates how market expectations for its technology exceed its tangible assets. This is a classic example of a biotech company's valuation based on the hope of a scientific breakthrough.
Market to book capitalization ratio for the market as a whole
Stoke Therapeutics develops drugs to treat severe genetic diseases. The company's value lies in its innovative technology and potential to create treatments for previously incurable diseases. The chart illustrates how its market valuation reflects expectations for scientific success rather than the cost of laboratory equipment, as opposed to the market average.
Debts of the company, segment and market as a whole
STOK - Company debts Stoke Therapeutics
Stoke Therapeutics, a company developing drugs to treat genetic diseases, uses debt to advance its innovative research. This chart illustrates funding for clinical trials based on their proprietary technology platform. The debt here represents an investment in a potential breakthrough in treating rare diseases.
Market segment debts - Dna
Stoke Therapeutics develops drugs to treat severe genetic diseases. In the cutting-edge field of gene therapy, funding research requires significant resources, and debt can be part of this strategy. The chart illustrates how the company manages its capital amid the long development cycles and high scientific risk typical of its sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Stoke Therapeutics
Stoke Therapeutics develops drugs to treat severe genetic diseases. This is a cutting-edge field of biotechnology, requiring massive investments in research and development with uncertain outcomes. This chart illustrates the company's conservative approach to financing. Its low debt level gives it the flexibility and time to bring its developments to fruition.
Market segment debt to market segment book capitalization - Dna
Stoke Therapeutics is a pioneer in developing RNA-targeted drugs to treat severe genetic diseases. This is a cutting-edge, yet highly risky, area of biotechnology. This chart shows the overall debt burden in the sector. It helps understand how Stoke and other companies in this niche finance their expensive and long-term research programs.
Debt to book value of all companies in the market
Stoke Therapeutics operates in the cutting-edge but risky field of gene therapy. This chart shows the overall market leverage, an indicator of the availability of capital for companies at the cutting edge of science. During periods when investors become risk-averse (which may coincide with a reduction in leverage), financing such projects becomes more difficult.
P/E of the company, segment and market as a whole
P/E - Stoke Therapeutics
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing the production of proteins from healthy genes. This graph reflects their belief in the innovativeness of their scientific approach. Its value shows the extent to which investors are willing to fund long-term research in the hopes of creating breakthrough treatments for diseases previously considered incurable.
P/E of the market segment - Dna
Stoke Therapeutics represents the gene therapy sector. This chart shows the average price-to-earnings ratio for this cutting-edge industry. Comparing the company's price-to-earnings ratio to this metric helps understand how highly the market values its unique scientific approach to treating rare genetic diseases compared to other companies involved in genetic engineering.
P/E of the market as a whole
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing protein expression. This is a pioneering approach to gene therapy. The company's value depends on the success of its scientific platform. This chart shows the overall interest in biotechnology. It helps us understand whether Stoke's valuation reflects faith in its unique technology or is part of a broader trend in genetics.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Stoke Therapeutics
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression. This chart reflects investor expectations for the clinical success of its innovative TANGO platform. The valuation is based on long-term forecasts and the technology's potential, not current revenue.
%20P%2FE%20Stoke%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Stoke-Therapeutics&v=1772616822289 "Chart of the company's future (projected) P/E Stoke Therapeutics")
Future (projected) P/E of the market segment - Dna
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. This chart shows how the market values its unique scientific platform compared to other biotech companies. It reflects investor optimism regarding its clinical programs and the potential of its TANGO technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772616822465 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Stoke Therapeutics develops RNA-based drugs to treat severe genetic diseases. The company's success depends on scientific breakthroughs and the ability to fund long-term research. This chart, showing overall market sentiment, is an indicator of investor risk appetite. Optimism allows companies like Stoke to raise capital for their ambitious projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772616822552 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Stoke Therapeutics
Stoke Therapeutics develops RNA-based drugs for the treatment of severe genetic diseases. The company's financial position is typical for an early-stage biotech company, with most of its resources allocated to research and clinical trials. This chart shows the R&D investment required to develop breakthrough treatments and achieve future profitability.
Profit of companies in the market segment - Dna
Stoke Therapeutics develops RNA-based drugs that can increase protein production in severe genetic diseases. This graph, which charts biotech revenue, illustrates how breakthrough technologies can transform the industry. The success of Stoke's TANGO platform could pave the way for treatment of an entire class of diseases and define a new growth vector for the entire segment.
Overall market profit
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing the expression of healthy proteins. This is a pioneering approach to RNA therapy. The company's success depends solely on scientific breakthroughs and clinical trial results, making its story independent of the broader market trends visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Stoke Therapeutics
Stoke Therapeutics is a pioneer in developing drugs to treat genetic diseases by enhancing protein expression. The future profit projections in this chart are entirely dependent on the success of its clinical programs. Analysts' expectations reflect their belief in the potential of the company's innovative technology to create new treatments for rare diseases.
%20profit%20of%20the%20company%20Stoke%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Stoke-Therapeutics&v=1772616822711 "Graph of future (projected) profit of the company Stoke Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. This chart shows future revenue expectations for the entire gene therapy segment. It allows one to assess how the company's innovative technology fits into the overall outlook for this cutting-edge, yet high-risk, field of biotechnology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772616822722 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Stoke Therapeutics is a biopharmaceutical company developing RNA-based treatments for severe genetic diseases. For a clinical-stage company whose success depends on research results, this chart is an indicator of the investment climate. Expectations of economic growth increase investors' risk tolerance, facilitating capital raising for long-term R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772616822729 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Stoke Therapeutics
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing the expression of healthy proteins. For a biotech company with a revolutionary approach, this metric, which relates market capitalization to minimum revenue, reflects pure potential. It demonstrates investors' belief that its technology can transform patients' lives and generate significant revenue.
P/S market segment - Dna
Stoke Therapeutics is developing a new class of RNA-based drugs for the treatment of severe genetic diseases. Their approach aims to increase protein production from a healthy gene to compensate for a defective one. This chart shows the market premium the gene therapy sector is likely to pay for revenue, demonstrating investor confidence in the breakthrough potential of Stoke's technology.
P/S of the market as a whole
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression. Its approach is aimed at addressing the underlying cause of the disease. The company's valuation is based on future potential. This chart, showing average revenue estimates, shows how investors value scientific breakthroughs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Stoke Therapeutics
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing protein expression. For a company in clinical development, this chart shows how investors view its potential future revenue. It reflects their belief in its innovative technology and success in treating rare diseases.
%20P%2FS%20Stoke%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Stoke-Therapeutics&v=1772616822888 "The graph of the company's future (projected) P/S Stoke Therapeutics")
Future (projected) P/S of the market segment - Dna
Stoke Therapeutics is a biotechnology company developing antisense oligonucleotide-based drugs to treat severe genetic diseases by enhancing protein expression. This figure reflects its estimated future revenue. A higher estimate reflects confidence in the breakthrough potential of its TANGO platform for previously incurable diseases, but carries significant risks.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772616823010 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Stoke Therapeutics develops RNA-based drugs for the treatment of severe genetic diseases. The company's potential is enormous, but clinical development is fraught with high risks. This market expectations chart is an indicator of investor confidence in breakthrough biotech platforms and their long-term commercial prospects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772616823147 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Stoke Therapeutics
Stoke Therapeutics, a biotech company focused on rare genetic diseases, generates revenue not from drug sales. While in the research stage, the company generates revenue from strategic alliances with major pharmaceutical partners. Growth in this revenue reflects the achievement of scientific goals and the corresponding compensation.
Sales of companies in the market segment - Dna
Stoke Therapeutics is a biotech company developing RNA-based drugs to treat severe genetic diseases. The company's technology aims to increase protein production from healthy genes. This graph represents the total revenue of the entire genetic drug market, illustrating the commercial potential for breakthrough technologies like those developed by Stoke.
Overall market sales
Stoke Therapeutics is developing drugs to treat severe genetic diseases by enhancing protein expression. Like many development-stage biotech companies, its valuation depends on its scientific prospects. The overall economic environment, shown in this chart, determines investor risk appetite and the availability of capital to finance breakthrough medical technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Stoke Therapeutics
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing the expression of healthy proteins. Future revenue is entirely dependent on the success of its clinical programs. This chart reflects analysts' long-term expectations regarding the commercial potential of its innovative RNA platform.
%20sales%20of%20the%20company%20Stoke%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Stoke-Therapeutics&v=1772616823208 "Schedule of future (projected) sales of the company Stoke Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression. This graph shows the potential future revenue from their therapeutic programs. It shows which of their drug candidates, according to analysts, have the highest chance of success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772616823223 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
This graph, reflecting investor willingness to fund cutting-edge medical research, is important for Stoke Therapeutics. The company develops drugs to treat genetic diseases. Raising capital for expensive clinical trials is directly dependent on the overall health of financial markets and confidence in the potential of biotechnology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772616823231 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Stoke Therapeutics
Stoke Therapeutics is a biotechnology company developing drugs to treat severe genetic diseases by increasing the expression of healthy proteins. This chart shows financial results during the intensive research phase. Profitability is a long-term goal, dependent on the success of clinical trials and the validation of its innovative TANGO platform.
Market segment marginality - Dna
Stoke Therapeutics is a biotech company developing RNA-based drugs for the treatment of severe genetic diseases. Its future profitability depends on the success of its innovative TANGO platform in clinical trials. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential and risks associated with Stoke's cutting-edge technology.
Market marginality as a whole
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. The company's success depends on scientific breakthroughs and attracting investment. This chart shows the overall state of the capital market, which determines how easily companies like Stoke can secure funding for their long-term and risky research.
Employees in the company, segment and market as a whole
Number of employees in the company Stoke Therapeutics
Stoke Therapeutics develops RNA-based drugs to treat severe genetic diseases. This graph reflects the size of its team of highly specialized scientists and clinicians. The growth in the graph shows progress in advancing their unique technology through preclinical and clinical trials, which is key for an early-stage biotech company.
Share of the company's employees Stoke Therapeutics within the market segment - Dna
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing the expression of healthy proteins. This is a pioneering approach to gene therapy. This chart shows Stoke's share of the total number of scientists working in this cutting-edge field. It reflects its scientific expertise and focus on creating drugs for previously incurable diseases.
Number of employees in the market segment - Dna
Stoke Therapeutics is a biotechnology company developing RNA-based treatments for severe genetic diseases. This chart reflects employment in the cutting-edge gene therapy sector. The growing number of specialists in this field demonstrates the acceleration of genetic research and development, confirming the potential of Stoke's innovative platform.
Number of employees in the market as a whole
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. This is at the forefront of biotechnology. This general work schedule doesn't matter to them. Their team grows as research progresses from concept to clinical trials, attracting highly specialized scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Stoke Therapeutics (STOK)
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases. Its value is based on a unique scientific platform. This chart illustrates the market's reliance on its intellectual property. A small team of elite scientists is developing potential drugs with enormous value.
%20of%20the%20company%20Stoke%20Therapeutics%20(STOK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Stoke-Therapeutics-STOK&v=1772616823711 "Chart of market capitalization per employee (in thousands of dollars) of the company Stoke Therapeutics (STOK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression (TANGO technology). This is cutting-edge science. Their value lies in their IP and the potential of their platform. This chart shows how the market values such science-intensive companies.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772616823739 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Stoke Therapeutics develops drugs to treat severe genetic diseases by enhancing protein expression. This is at the forefront of biotechnology. This figure demonstrates the enormous value the market places on the intellectual property and scientific advances generated by a small but highly specialized team of researchers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772616823782 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Stoke Therapeutics (STOK)
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases using RNA technologies. This is at the cutting edge of science. This chart should be read as "innovation costs": it shows how much the company invests (negative profit) per researcher to create next-generation therapies.
%20Chart%20Stoke%20Therapeutics%20(STOK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Stoke-Therapeutics-STOK&v=1772616823845 "Company Profit Per Employee (in thousands of dollars) Chart Stoke Therapeutics (STOK)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Stoke Therapeutics is a clinical-stage biotech company developing RNA-based therapies to treat rare genetic diseases. This chart shows the benchmark for the biotech sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by profit, but by the burn rate of the R&D budget.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772616823903 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression (TANGO technology). This is at the cutting edge of genetics. This chart helps evaluate the profitability of this model, where all the value is contained in the scientific platform and multiple clinical programs, per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772616823938 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Stoke Therapeutics (STOK)
Stoke Therapeutics develops drugs to treat severe genetic diseases by increasing protein expression. Like many research-stage biotechs, its commercial revenue per employee is zero. The chart confirms this, emphasizing the company's focus on scientific breakthroughs that could lead to valuable future drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Stoke-Therapeutics-STOK&v=1772616823976 "Sales chart per company employee Stoke Therapeutics (STOK)")
Sales per employee in the market segment - Dna
Stoke Therapeutics is a biotech company working to treat severe genetic diseases by enhancing protein expression (TANGO technology). This is cutting-edge science. This graph is typical for an R&D company: revenue (if any) comes from partnerships. The productivity of their scientific team is measured by research progress, not current revenue.
Sales per employee for the market as a whole
Stoke Therapeutics (STOK) is a biotech company developing a new class of drugs (oligonucleotides) designed to treat severe genetic diseases by increasing protein expression (TANGO technology). Like other clinical biotechs, Stoke has no commercial revenue. This chart will reflect only milestone payments from partners (if any) against the costs of a large staff of scientists leading R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Stoke Therapeutics (STOK)
Stoke Therapeutics is a biotech company developing RNA-based drugs (TANGO) for the treatment of severe genetic diseases, particularly rare forms of epilepsy. This chart shows the number of bearish bets. Skepticism reflects the high risks of biotech: bears are betting on possible failure in early clinical trials, safety issues, or that the technology will not prove its superiority.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Stoke-Therapeutics-STOK&v=1772616824051 "Short Shares Chart for the Company Stoke Therapeutics (STOK)")
Shares shorted by market segment - Dna
Stoke Therapeutics (STOK) is a biotech company developing drugs to treat severe genetic diseases by enhancing protein expression (TANGO technology). This chart shows bets against the DNA technology sector. If investors are short this sector, they are generally skeptical of new genetic platforms, expecting a long and expensive road to drug approval.
Shares shorted by the overall market
Stoke (STOK) is a clinical-stage biotech (genetics). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives STOK of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Stoke Therapeutics (STOK)
Stoke Therapeutics develops RNA-targeted therapies for rare genetic diseases. The stock is speculative and dependent on R&D. This chart can soar above 70 on positive trial data, indicating euphoria. Oversold territory (<30) often reflects setbacks, delays, or concerns about funding during the "venture winter."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Stoke-Therapeutics-STOK&v=1772616824132 "RSI 14 indicator chart for the company's stock Stoke Therapeutics (STOK)")
RSI 14 Market Segment - Dna
Stoke Therapeutics is a biotech company working on treating severe genetic diseases. Its approach (TANGO) uses RNA technology to boost production of a "healthy" protein. This graph measures the collective momentum in the gene and DNA therapy sector. It helps distinguish the reaction to STOK's clinical data from the general "emotional" wave across the biotech industry.
RSI 14 for the overall market
Stoke Therapeutics (STOK) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast STOK (Stoke Therapeutics)
Stoke Therapeutics is a biotech company developing drugs to treat severe genetic diseases by increasing the expression of healthy proteins (TANGO technology). This chart shows the average analyst forecast. Their targets are based on clinical data and the potential of this innovative platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-STOK-Stoke-Therapeutics&v=1772616824167 "A chart showing analyst consensus forecasts for the expected stock price. STOK (Stoke Therapeutics)")
The difference between the consensus estimate and the actual stock price STOK (Stoke Therapeutics)
Stoke Therapeutics (STOK) is a biotech company developing RNA-based drugs (TANGO technology) to treat rare genetic diseases such as Dravet syndrome. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their unique scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-STOK-Stoke-Therapeutics&v=1772616824168 "A chart showing the difference between the consensus forecast and the actual stock price. STOK (Stoke Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Stoke Therapeutics is a biotech company using a unique RNA approach to treat severe genetic epilepsy (Dravet syndrome). This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in the potential of this new treatment modality for rare diseases.
Analysts' consensus forecast for the overall market share price
Stoke Therapeutics (STOK) is an R&D biotech focused on rare genetic diseases (epilepsy) using ASO technology. This chart, reflecting expert expectations, is a measure of risk appetite. When the market is pessimistic, investors flee cash-burning, pre-profitable biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Stoke Therapeutics
Stoke is a biotech company developing RNA-based drugs to treat severe genetic diseases. Their key focus isn't gene silencing, but rather upregulating the production of a healthy protein. This chart is an indicator of their unique platform. It likely aggregates data from their clinical trials and market perceptions of their innovative scientific approach.
AKIMA Market Segment Index - Dna
Stoke Therapeutics (STOK) is a clinical-stage biotech and a pioneer in rare genetic diseases. The company is developing a unique platform (TANGO) that enhances, rather than corrects, the expression of a healthy gene (for the treatment of epilepsy). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough R&D platform (TANGO) distinguish (STOK) from the average pharma company?
The AKIM Index for the overall market
Stoke Therapeutics is a biotech company developing RNA therapy for the treatment of severe genetic diseases (epileptic disorders). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific venture, targeting the cause of the disease, compares to overall economic trends.
